Skip to main content Skip to section navigation Skip to footer
  • About Us
      Company Overview
      Team
      Careers
  • Gene Therapies
      Our Approach
      Publications & Presentations
  • Patients
      Patients & Families
      Patient Spotlight
  • Pipeline & Programs
      OPGx-BEST1
      OPGx-LCA5
  • Investors
      Press Releases
      Events
      Presentations
      SEC Filings
      Financial Info
      Stock Data
      Governance
      Resources
  • Contact Us
Skip to main content Skip to section navigation Skip to footer
Opus Genetics, Inc. IR Overview
  • Overview
  • Press Releases
  • Events
  • Presentations
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote & Chart
    • Historical Data
    • Analyst Coverage
  • Governance
    • Overview
    • Leadership Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • IR Contact
    • Email Alerts
    • Investor FAQs
    • RSS News Feed
  • Back to Corporate Site

Press Releases

Investors

  • Overview
  • Press Releases
  • Events
  • Presentations
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote & Chart
    • Historical Data
    • Analyst Coverage
  • Governance
    • Overview
    • Leadership Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • IR Contact
    • Email Alerts
    • Investor FAQs
    • RSS News Feed
Nov 12, 2020 6:00 am EST
Ocuphire Pharma Announces Two Publications Supporting the APX3330 Program
Nov 10, 2020 10:09 am EST
Ocuphire to Participate in Upcoming Virtual HCW Conference in November
Nov 6, 2020 6:00 am EST
Industry Veteran Susan Benton Joins the Ocuphire Pharma Board of Directors
Nov 5, 2020 8:33 pm EST
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
Nov 5, 2020 11:50 am EST
Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma
Nov 3, 2020 8:40 am EST
Ocuphire Pharma to Host Key Opinion Leader Event on Nyxol® and APX3330
Nov 2, 2020 9:00 am EST
Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma
Sep 9, 2020 8:00 am EDT
Ocuphire to Participate in Upcoming Virtual Healthcare Investor Conferences in September
Jun 17, 2020 11:30 pm EDT
Rexahn and Ocuphire Enter into Definitive Merger Agreement
Jan 22, 2020 7:00 am EST
Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Next Pagearrow_forward
rss_feed News RSS
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • accessibilityAccessibility Statement
Opus Genetics, Inc. home
Sign up to receive our newsletter

Follow us

go to Opus Genetics' LinkedIn page go to Opus Genetics' YouTube page
  • Gene Therapies
  • Patients & Families
  • Pipeline
  • Publications
  • About Us
  • Careers
  • Contact Us
  • Investors
© 2026 Opus Genetics, Inc.
  • Cookie Policy
  • Privacy Statement
Site by BKW